VEGFA and glaucoma: The results revealed that all three anti-VEGF drugs exhibited several similar AEs, including endophthalmitis, retinal vein occlusion, retinal artery occlusion, glaucoma, dry eye syndrome, and additional AEs not mentioned in the drug’s prescribing information.